Literature DB >> 34094673

Exosomal transfer of miR-429 confers chemoresistance in epithelial ovarian cancer.

Taoqiong Li1,2, Li Lin1,2, Qin Liu3, Wujiang Gao1,2, Lu Chen1,2, Chunli Sha1,2, Qi Chen2, Wenlin Xu2, Yuefeng Li4, Xiaolan Zhu1,2,5.   

Abstract

The development of multidrug resistance during chemotherapy is the main obstacle for epithelial ovarian cancer (EOC) treatment. Exosomal transfer of carcinogenic microRNAs (miRNAs) might strengthen chemoresistance in recipient cells. Here, we identified through microarray analysis higher miR-429 expression in multidrug-resistant SKOV3 cells and their secreted exosomes (SKOV3-EXO) than in sensitive A2780 cells and their secreted exosomes. SKOV3-derived exosomes were internalized by A2780 cells, which permitted the transfer of miR-429. Exosomal miR-429 enhanced the proliferation and drug resistance of A2780 cells by targeting calcium-sensing receptor (CASR)/STAT3 pathway in vitro and in vivo. In addition, NF-κB-p65 was predicted to bind to the miR-429 promoter region, and the inhibition of NF-κB reduced the expression of miR-429 and led to the sensitivity of EOC cells. Consistently, A2780 cells co-incubated with SKOV3 pretreated with an NF-κB inhibitor or miR-429 antagomir showed sensitivity to cisplatin and exhibited attenuated cell proliferation. Based on our data, exosomal miR-429 functions as a primary regulator of the chemoresistance and malignant phenotypes of EOC by targeting CASR through a mechanism promoted by NF-κB and might be a therapeutic target for EOC. AJCR
Copyright © 2021.

Entities:  

Keywords:  EOC; Exosome; NF-κB; chemoresistance; miR-429

Year:  2021        PMID: 34094673      PMCID: PMC8167704     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  52 in total

Review 1.  The NF-kappaB family of transcription factors and its regulation.

Authors:  Andrea Oeckinghaus; Sankar Ghosh
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10       Impact factor: 10.005

Review 2.  Exosome: a novel mediator in drug resistance of cancer cells.

Authors:  He-da Zhang; Lin-Hong Jiang; Jun-Chen Hou; Shan-Liang Zhong; Ling-Ping Zhu; Dan-Dan Wang; Si-Ying Zhou; Su-Jin Yang; Jin-Yan Wang; Qian Zhang; Han-Zi Xu; Jian-Hua Zhao; Zhen-Ling Ji; Jin-Hai Tang
Journal:  Epigenomics       Date:  2018-10-12       Impact factor: 4.778

3.  Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.

Authors:  Jacobus Pfisterer; Catherine M Shannon; Klaus Baumann; Joern Rau; Philipp Harter; Florence Joly; Jalid Sehouli; Ulrich Canzler; Barbara Schmalfeldt; Andrew P Dean; Alexander Hein; Alain G Zeimet; Lars C Hanker; Thierry Petit; Frederik Marmé; Ahmed El-Balat; Rosalind Glasspool; Nikolaus de Gregorio; Sven Mahner; Tarek M Meniawy; Tjoung-Won Park-Simon; Marie-Ange Mouret-Reynier; Cristina Costan; Werner Meier; Alexander Reinthaller; Jeffrey C Goh; Tifenn L'Haridon; Sally Baron Hay; Stefan Kommoss; Andreas du Bois; Jean-Emmanuel Kurtz
Journal:  Lancet Oncol       Date:  2020-04-16       Impact factor: 41.316

4.  Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.

Authors:  Sarah L Coleridge; Andrew Bryant; Thomas J Lyons; Richard J Goodall; Sean Kehoe; Jo Morrison
Journal:  Cochrane Database Syst Rev       Date:  2019-10-31

5.  miR-429 inhibits migration and invasion of breast cancer cells in vitro.

Authors:  Zhi-Bin Ye; Gang Ma; Ya-Hui Zhao; Yun Xiao; Yun Zhan; Chao Jing; Kai Gao; Zhi-Hua Liu; Sheng-Ji Yu
Journal:  Int J Oncol       Date:  2014-11-17       Impact factor: 5.650

Review 6.  Apoptotic Signaling Pathways in Glioblastoma and Therapeutic Implications.

Authors:  Silvia Anahi Valdés-Rives; Diana Casique-Aguirre; Liliana Germán-Castelán; Marco A Velasco-Velázquez; Aliesha González-Arenas
Journal:  Biomed Res Int       Date:  2017-11-12       Impact factor: 3.411

7.  MicroRNA-429 decreases the invasion ability of gastric cancer cell line BGC-823 by downregulating the expression of heparanase.

Authors:  Nan Sheng; Lin Zhang; Shaofeng Yang
Journal:  Exp Ther Med       Date:  2017-12-11       Impact factor: 2.447

Review 8.  Chemotherapy Resistance in Advanced Ovarian Cancer Patients.

Authors:  Ruchika Pokhriyal; Roopa Hariprasad; Lalit Kumar; Gururao Hariprasad
Journal:  Biomark Cancer       Date:  2019-07-05

Review 9.  The Different Mechanisms of Cancer Drug Resistance: A Brief Review.

Authors:  Behzad Mansoori; Ali Mohammadi; Sadaf Davudian; Solmaz Shirjang; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2017-09-25

Review 10.  The Role of Exo-miRNAs in Cancer: A Focus on Therapeutic and Diagnostic Applications.

Authors:  Francesco Ingenito; Giuseppina Roscigno; Alessandra Affinito; Silvia Nuzzo; Iolanda Scognamiglio; Cristina Quintavalle; Gerolama Condorelli
Journal:  Int J Mol Sci       Date:  2019-09-21       Impact factor: 5.923

View more
  4 in total

Review 1.  Non-Coding RNAs Delivery by Small Extracellular Vesicles and Their Applications in Ovarian Cancer.

Authors:  Mu Liu; Xiaofang Zhou; Jie Tang
Journal:  Front Bioeng Biotechnol       Date:  2022-05-19

Review 2.  Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies.

Authors:  Alessandro Allegra; Claudia Petrarca; Mario Di Gioacchino; Marco Casciaro; Caterina Musolino; Sebastiano Gangemi
Journal:  Cells       Date:  2022-03-27       Impact factor: 6.600

Review 3.  Advances in Exosomes as Diagnostic and Therapeutic Biomarkers for Gynaecological Malignancies.

Authors:  Mengdan Miao; Yifei Miao; Yanping Zhu; Junnan Wang; Huaijun Zhou
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

Review 4.  Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion.

Authors:  Wanjia Tian; Ningjing Lei; Junying Zhou; Mengyu Chen; Ruixia Guo; Bo Qin; Yong Li; Lei Chang
Journal:  Cell Death Dis       Date:  2022-01-18       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.